Volition(US:VNRX)2021-03-30 18:06Company Overview - Volition is an epigenetics healthcare company developing easy-to-use blood-based tests[4] - The company has a broad intellectual property portfolio, including 64 granted patents worldwide[4] - Commercialization will take multiple forms, including IVD products, research use only assays, reagent sales, and licensing of intellectual property[13] Cancer Market Opportunity - Cancer is a leading cause of death worldwide, accounting for approximately 95 million annual deaths globally[7] - There are over 18 million new cases of cancer diagnosed each year, expected to grow to over 295 million by 2040[7] - The company believes early, non-invasive, accurate cancer diagnosis remains a significant unmet medical need and a significant commercial opportunity[8] NuQ Vet Cancer Screening Test - The NuQ Vet Cancer Screening Test is positioned for use in the annual health check of older dogs (7 years and older)[34] - In a study of over 330 dogs, at 100% specificity, the NuQ Vet Cancer Screening Test identified 74% of lymphomas and 89% of hemangiosarcoma versus control[35] - The test costs $122, with $45 per test to Volition at 85% gross margin[35] Blood Cancer Studies - In blood cancer studies, a single NuQH31 assay produces excellent AUCs ranging from 85% to 88% for both newly diagnosed and total patients[46] - In the largest and most recent cohort, the NuQ H31 assay detects 61% of cancers at 95% specificity and 72% of cancers at 90% specificity for both formats[46] - There are approximately 415000 blood cancer deaths each year[44] COVID-19 and NETosis - Preliminary study results demonstrated the Area Under the Curve (AUC) for a single NuQ assay was 987% PCR positive versus control subjects, with 100% sensitivity at 94% specificity[67] - A second NuQ assay also showed promising results with an AUC of 862%[67]